Madrigal Pharmaceuticals (MDGL)

• Market cap: $13.6B
• 1 day: -0.65%
• 5 days: 8.42%
• 1 month: -0.35%
• 3 months: 41.18%
• 6 months: 99.96%
• Year to date: 90.87%
• 1 year: 90.71%
• 5 years: 428.75%
• 10 years: 4,729.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528